纯度≥ 80 % as determined by SDS-PAGE.
内毒素< 1.0 EU per μg protein as determined by the LAL method.
生物活性1.Immobilized Human GPRC5D Protein(Cat:24447-H18H-DD) at 5 μg/mL (100 μL/well) on Nickel coated plate can bind Anti-Human GPRC5D Antibody, Human IgG1, the EC50 is 4.0 ng/ml（QC tested).
2.Loaded Anti-GPRC5D Antibody on Protein A Biosensor, can bind GPRC5D Protein(Cat:24447-H18H-DD) with an affinity constant of 58.1 nM as determined in BLI assay (Sartorius Octet Red384) (Routinely tested).
蛋白构建A DNA sequence encoding the human GPRC5D (Q9NZD1) (Met1-Ser268) was expressed, with a Flag tag at the N-terminus and a polyhistidine tag at the C-terminus.
表达宿主HEK293 Cells
种属Human
预测 N 端Met
分子量The recombinant human GPRC5D consists of 286 amino acids and predicts a molecular mass of 32.83 kDa.
缓冲液Supplied as solution in 10mM HEPES, 50mM NaCl, DDM, pH7.5 with glycerol as protectant. DDM is cytotoxicity and not suitable for cell based experiments. Never remove DDM as it is necessary to the activity of the protein. Do not store the protein without glycerol.
Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式It is supplied and shipped as liquid with dry ice.
稳定性 & 储存条件Samples are stable for up to three months from date of receipt at -70℃. Store it under sterile conditions at -70℃ or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.



GPRC5D Protein, Human, Recombinant (His & FLAG Tag): 别称
GPRC5D Protein, Human
GPRC5D 背景信息
Orphan G-protein-coupled receptor family C group 5 member D (GPRC5D) has seven transmembrane segments forming the core of the receptor, as well as an intracellular C-tail and an extracellular N-terminal domain. GPRC5D is highly and selectively expressed on the surface of CD138+ multiple myeloma (MM) cells, whereas in normal tissues, a much lower expression is limited to plasma cells and certain hard keratinizing tissues. This makes GPRC5D a promising marker for monitoring tumor load and a target antigen for MM-specific T cell-engaging therapies such as bispecific antibodies and CAR-T cells.